HDAC6 and COVID-19: HDAC6 inhibition, which blocks IFN-I synthesis and its downstream effects in airway epithelial cells and immune cells, may be able to mitigate the negative effects generated in severely ill COVID-19 patients by late or extended activation of the IFN-I pathway (54).